X4 Pharmaceuticals (XFOR) news
Recent news
OFCOM: Decided to focus the remainder of investigation on X's compliance with its illegal content and complaints and reporting duties
The UK's communications regulator, Ofcom, has announced that it will focus the remainder of its investigation on X's compliance with its obligations regarding illegal content and complaints and reporting duties. This decision follows an ongoing review of the platform's adherence to the Online…
AInvest Wire · 22h agoX4 Pharmaceuticals gets up to $150M sr debt facility
AInvest Wire · 6d agoX4 Pharmaceuticals - Expects phase 3 4ward trial enrollment by year-end 2026, topline data in H1 2028
X4 Pharmaceuticals (Nasdaq: XFOR) announced on September 8, 2026, that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding the design of its global 4WARD Phase 3 clinical trial for mavorixafor in the treatment of chronic neutropenia. Following a Type C meeting with…
AInvest Wire · 6d agoX4 Pharmaceuticals secures up to $150 million senior debt facility with K2 HealthVentures
AInvest Wire · 6d agoX4 Pharma targets 4ward topline data in 1H 2028
AInvest Wire · Sep 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.